Drug Approval | July 26, 2023
NATCO files generic Erdafitinib Tablets in USA
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories
Aurobindo will respond to the US FDA within the stipulated timelines
This product would be manufactured at Lupin's Nagpur facility in India
Good momentum in commercial CDMO business
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
CMOs showed an increasing reluctance to take on debt in 2022
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Subscribe To Our Newsletter & Stay Updated
